TTFields on the Table: Novocure’s Q1 2026 Earnings Signal Growth in Revenue, Drag in Costs, and Pax Takes Center Stage

Headline numbers at a glance

• Revenue: Total net revenues of $174.1 million, up 12% year over year.
• Gross margin: 78% for the quarter, up from 75% in the prior year, driven by lower array costs and cheaper supplier prices.
• Net loss / EPS: Net loss of $71.1 million, or loss per share (EPS) of $0.62.
• Adjusted EBITDA: A small negative print of $(0.3) million.

What’s driving the top line and the mix

The quarter’s revenue strength is anchored in ongoing geographic expansion and new product momentum. U.S. and international markets contributed meaningfully, with the U.S. at $96.0 million, Germany $24.5 million, France $22.9 million, and Japan $10.2 million, while other active markets delivered ~$15.7 million.

Notable line items include:

• Optune Pax—FDA approval and launch in the United States for locally advanced pancreatic cancer, with more than 800 prescribers certified and over 160 prescriptions as of March 31, 2026.
• Optune Lua—recognised revenue of $3.1 million in the quarter.
• Greater China revenue from the company’s partnership with Zai Lab totaling $4.8 million.

One-time items and regional quirks

Germany benefited from higher approval rates and a one-time benefit of $2.5 million, while France benefited from contract performance improvements, including a one-time benefit of $1 million.

Costs, margins, and the evolving cost structure

R&D and marketing remain the major cost centers. R&D for the quarter was $58.3 million, up 8% year over year as patient recruitment for the Phase 3 KEYNOTE D58 trial progresses. Sales and marketing came in at $58.4 million, reflecting the push to support Pax and Lua launches.

General and administrative expenses were elevated at $85.9 million, a rise of 92% versus the prior year. The growth was driven by a $43 million share-based compensation expense tied to the FDA approval of Optune Pax. This stock-based grant is a non-cash GAAP item, and the shares did not vest or distribute, illustrating how the accounting friction can occur even when the cash flow line is not moving in the same direction.

Liquidity and cash position

Cash, cash equivalents and short-term investments stood at $432.0 million as of March 31, 2026, providing a cushion for a company navigating the combination of growing commercial programs and ongoing R&D commitments.

Guidance, expectations, and what isn’t in the filing

As is common in early-stage investment narratives for biotech-oncology devices, the press release does not provide a revenue forecast or forward-looking EPS guidance. Analysts typically parse these disclosures for an EPS consensus figure and a potential earnings surprise relative to that consensus. In this earnings release, those forward-looking benchmarks are not disclosed, so the market is left to price the quarter against the reported numbers and the ongoing commercial trajectory of Pax, Lua, and TTFields adoption across markets.

What this could portend for Novocure and sector peers

The quarter underscores a bifurcated story: top-line momentum driven by expanded adoption and product diversification, paired with a GAAP loss profile that remains a function of one-time and stock-based costs tied to regulatory milestones. The Pax launch is a meaningful inflection point. If the U.S. uptake accelerates and international markets follow, the revenue mix could tilt toward more recurring adoption-driven contributions and less reliance on one-off market gains.

For peers in the TTFields space and broader oncology device players, the Q1 results hint at two structural themes: (1) regulatory milestones can briefly mask underlying operating leverage, but (2) persistent cost discipline and revenue diversification are essential to convert growth into sustained profitability. The absence of explicit revenue guidance means investors will watch subsequent quarters closely for cadence—does Pax scale as much as the press release suggests, and will Lua-related revenues continue to ramp in other regions?

Bottom line: a quarter of progress with multiple moving parts

Novocure posted revenue growth and a healthier gross margin, but remains unprofitable on a GAAP basis due to sizable SG&A and one-time stock-based compensation tied to regulatory milestones. The cash stack remains ample for near-term fundraising needs, and the Pax launch adds a tangible catalyst. In the near term, investors will likely benchmark NVCR against peers on a combination of EPS discipline, trajectory of Optune Pax adoption, and the capacity to translate R&D spend into clinical and commercial momentum.

As for the broader sector, the quarter reinforces a pattern where regulatory approvals can unlock demand while also triggering non-cash accounting charges that complicate the narrative. The real test is whether the growth in prescriptions and international expansion translates into enduring margin expansion and a clearer path to profitability—an outcome that would also lift the broader TTFields and oncology-device cohort’s earnings outlook.